ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 695

Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies

Petra Budde1, Hans-Dieter Zucht1, Johannes Schulte-Pelkum1, Daniel Wirtz1, Torsten Witte2, Matthias Schneider3 and Peter Schulz-Knappe1, 1Protagen AG, Dortmund, Germany, 2Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, 3Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, biomarkers and diagnosis, Diagnostic Tests, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Given the heterogeneity of clinical presentations, the diagnosis of Systemic Lupus Erythematosus (SLE) can be challenging, in particular in those patients presenting with early or incomplete disease, or with overlapping or atypical features. Autoantibodies (AABs) are important in aiding the clinical diagnosis of SLE, with some few AABs, anti-double-stranded DNA (dsDNA), anti-Smith (Sm), and anti-ribosomal P (riboP) being highly associated with SLE. As none of the traditional AABs has sufficient sensitivity to achieve diagnosis of SLE, current testing is based on measuring multiple AAB assays either in parallel or serial. We have recently identified novel AABs in SLE, which hold promise for improving diagnostic testing of SLE (1). We have developed quantitative ELISA-prototypes for five new AABs, which were tested in combination with traditional AABs. The objectives of this study were to evaluate the diagnostic value of novel AABs and to screen for an optimized combination of novel and traditional AABs using logistic regression to increase the diagnostic accuracy of SLE testing.

Methods:  Serum samples were obtained from 156 SLE patients with European ancestry at the rheumatology department of the Heinrich-Heine University (Düsseldorf, Germany), and Hannover Medical School (Hannover, Germany). SLE samples were compared against 126 samples from autoimmune diseases (AID; myositis: n=20; Sjögren’s syndrome (SjS): n=31; rheumatoid arthritis (RA) n=36; systemic sclerosis (SSc): n=39), and 77 healthy control samples. Prototype bead based ELISAs were developed for 5recently identified novel antigens. Traditional diagnostic AABs were measured using IVD ELISAs and included: SSA/Ro60, SSA/Ro52, La/SSB, Sm, RNP, dsDNA, Scl70, CENPB, Jo-1, CCP, phospholipid and dsDNA. Optimized marker combinations of new and traditional markers were tested using logistic regression and receiver operating curve analysis (ROC).

Results:  When comparing 156 SLE patients with 203 control samples, the area under the curve (AUC) of the five novel SLE ELISAs ranged from 0.63 to 0.75. A cut-off was set at a specificity of 95% and yielded a sensitivity ranging from 13.5% to 21.2% for the five novel assays. The sensitivity and specificity of new ELISAs was comparable to traditional ELISAs, which was in this cohort for anti-dsDNA 35% and 97%, anti-Sm 15% and 97%, and anti-RiboP 26% and 97%. A logistic regression model was used to combine the results of multiple tests. Compared to a logistic regression with traditional assays, a logistic regression with novel markers achieved higher sensitivity by pertaining high specificity. The logistic regression model based on a multimarker IVD assay with ten extracted nuclear antigens (ENA) yielded an AUC of 0.87 and a sensitivity of 58% at a specificity of 95%. By contrast, the optimal combination of traditional and novel ELISAs reached an AUC of 0.92 and a sensitivity of 75% at a specificity of 95%.

Conclusion: This study demonstrates the feasibility of combining test results of novel and traditional AABs using logistic regression to increase the diagnostic accuracy for SLE. Further studies are required to assess the impact of different ethnicities on marker selection and algorithm performance.


Disclosure: P. Budde, ProtagenAG, 3; H. D. Zucht, Protagen AG, 3; J. Schulte-Pelkum, ProtageAG, 3; D. Wirtz, Protagen AG, 3; T. Witte, None; M. Schneider, Protagen AG, 5; P. Schulz-Knappe, ProtagenAG, 3.

To cite this abstract in AMA style:

Budde P, Zucht HD, Schulte-Pelkum J, Wirtz D, Witte T, Schneider M, Schulz-Knappe P. Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/development-of-a-multimarker-model-for-the-detection-of-systemic-lupus-erythematosus-based-on-new-and-traditional-autoantibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-multimarker-model-for-the-detection-of-systemic-lupus-erythematosus-based-on-new-and-traditional-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology